ondasdechoque.org
PT-BR

Chronic plantar fasciitis: one electrohydraulic session versus sham · Randomized trial · 2006

Does one shockwave session help long-lasting heel pain?

In this trial, one session with this device lowered heel pain a little more than a sham session. At 3 months, pain fell by about 2.5 points vs about 1.6 with sham, on a 0–10 scale. At 1 month the gap was about 0.3 points and not statistically clear, and walking and activity were not clearly better.

Helped a little more than sham at 3 months
adults with long-lasting heel pain
172
session of about 25 minutes
1
of compared results
3 mo

Good to know: Funded by the device maker.

Malay DS, Pressman MM, Assili A, et al. J Foot Ankle Surg, 2006 · Read the paper ↗

How this study worked

Orthospec activeshockwaves115 peopleFoam-insulated sham57 peopleShockwaveSham
People were assigned by lot. One group had a sham: the same-looking treatment without the active waves. Each dot stands for 2 people.

What happened

Heel pain under pressure: extra drop vs sham

Difference in pain change, 0–10 scale, with likely range · 0 means no difference

Heel pain fell more with shockwave than with sham by about 0.3 points at 1 month, 1 point at 2 months and 0.9 points at 3 months. At 1 month the range includes no difference.
Show the numbers
Difference (points on the 0–10 pain scale)likely range
1 month−0.34−1.06 to 0.37
2 months−0.99−1.86 to −0.12
3 months−0.94−1.87 to −0.02

The treatment

Orthospec active shockwaves

Shockwave, 1 session

ShockwavesThe paper doesn’t say whether radial or focused
Sessions
1
Pulses
3,800 per session · strength raised step by step from level 1 to 7, as tolerated
Numbing
None
Device
Orthospec (Medispec)
Everyone also got
No other treatment; pain medicines paused for 48 hours before each visit

Compared with: A sham session: the same procedure, with foam blocking most of the energy

Settings are what each study used, not a prescription.

Who took part

172 adults with pain in one heel for over 6 months despite several treatments, at three US centres; average age 51.

Side effects

3 of 115 treated people had a mild bruise or swelling that settled within days; none in the sham group.

All the numbers and the full appraisal
FROM THE FULL PAPER

The results, in numbers.

172 adults with proximal plantar fasciitis for over 6 months despite at least 4 months of professional care and two drug plus two non-drug treatments; heel pain ≥5 cm on the VAS; one heel per person, bilateral cases excluded. Mean age 51 years, 33% men, 87% white, mean pain duration 30 months; three US centres, 2003–2004.

Orthospec active shockwaves115randomized

People, one heel each. 112 entered the 3-month LOCF efficacy analysis; observed visits: 111 at 1 month, 97 at 2, 101 at 3, 87 at 6 and 78 at 12 months. One person randomized to ESWT received sham by mistake; this participant was placed in the placebo group for the energy analyses (Figure 4, Table 10, Figures 5–6).

Foam-insulated sham57randomized

People, one heel each. 56 entered the 3-month LOCF efficacy analysis; observed visits: 54 at 1 month, 48 at 2, 51 at 3, 45 at 6 and 40 at 12 months.

Investigator-assessed heel pain (primary)5 reported outcomes
01
3 months after treatment

Investigator-assessed heel pain (primary)

Investigator VAS with PressureSpec standardized pressure VAS points (cm)

means
GroupnBaselineReported change
Orthospec active shockwaves112—-2.51
Foam-insulated sham56—-1.57

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Difference in adjusted mean change-0.94CI 95% -1.87 to -0.02p = 0.045

Active shockwaves versus sham

Means from analysis of variance adjusted for baseline score and clinical site; last observation carried forward

-2.1Equal results 00.2

Protocol-defined primary outcome. Pain fell in both groups; the reduction was 0.94 points larger with active treatment, with a confidence interval reaching −0.02, close to no difference.

Analysis details and source

Adjusted mean change from baseline; negative values mean less pain. SDs of the change were not reported. Analysis included people with at least one follow-up visit, with LOCF.

02
1 month after treatment

Investigator-assessed heel pain

Investigator VAS with PressureSpec standardized pressure VAS points (cm)

means
GroupnBaselineReported change
Orthospec active shockwaves111—-1.61
Foam-insulated sham54—-1.27

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Difference in adjusted mean change-0.34CI 95% -1.06 to 0.37p = 0.34

Active shockwaves versus sham

Means from analysis of variance adjusted for baseline score and clinical site; last observation carried forward

-1.2Equal results 00.5

At 1 month the difference was small and not statistically significant (−0.34, 95% CI −1.06 to 0.37).

Analysis details and source

Adjusted mean change from baseline; negative values mean less pain. SDs of the change were not reported. Analysis included people with at least one follow-up visit, with LOCF.

03
2 months after treatment

Investigator-assessed heel pain

Investigator VAS with PressureSpec standardized pressure VAS points (cm)

means
GroupnBaselineReported change
Orthospec active shockwaves111—-2.3
Foam-insulated sham54—-1.31

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Difference in adjusted mean change-0.99CI 95% -1.86 to -0.12p = 0.026

Active shockwaves versus sham

Means from analysis of variance adjusted for baseline score and clinical site; last observation carried forward

-2.1Equal results 00.2

At 2 months the reduction was larger with active treatment.

Analysis details and source

Adjusted mean change from baseline; negative values mean less pain. SDs of the change were not reported. Analysis included people with at least one follow-up visit, with LOCF.

17
3 months after treatment

Investigator pain, no heel spur on X-ray

Investigator VAS with PressureSpec standardized pressure VAS points (cm)

means
GroupnBaselineReported change
Orthospec active shockwaves68—-3.67
Foam-insulated sham36—-2.19

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Difference in adjusted mean change-1.48CI 95% -2.63 to -0.33p = 0.012

Active shockwaves versus sham

Means from analysis of variance adjusted for baseline score and clinical site; last observation carried forward

-2.9Equal results 00.3

Without a radiographic spur the reduction was 1.48 points larger with active treatment.

Analysis details and source

Subgroup defined by baseline radiograph (68 versus 36 people); no treatment-by-spur interaction test is reported.

18
3 months after treatment

Investigator pain, heel spur on X-ray

Investigator VAS with PressureSpec standardized pressure VAS points (cm)

means
GroupnBaselineReported change
Orthospec active shockwaves45—-2.06
Foam-insulated sham20—-1.99

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Difference in adjusted mean change-0.07CI 95% -1.66 to 1.52p = 0.96

Active shockwaves versus sham

Means from analysis of variance adjusted for baseline score and clinical site; last observation carried forward

-2Equal results 01.9

With a radiographic spur, pain fell in both groups and the difference was small and not statistically significant (−0.07, 95% CI −1.66 to 1.52). The authors say a larger sample would be needed to judge this subgroup.

Analysis details and source

Subgroup of 45 versus 20 people; wide interval. The Summary nonetheless presents the device as an option with or without a spur.

Self-assessed heel pain3 reported outcomes
04
1 month after treatment

Self-assessed heel pain

Participant VAS, pain on first steps in the morning VAS points (cm)

means
GroupnBaselineReported change
Orthospec active shockwaves110—-2.23
Foam-insulated sham54—-2.12

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Difference in adjusted mean change-0.11CI 95% -0.95 to 0.72p = 0.79

Active shockwaves versus sham

Means from analysis of variance adjusted for baseline score and clinical site; last observation carried forward

-1.2Equal results 00.9

Self-rated pain fell in both groups at 1 month; the difference was not statistically significant (−0.11, 95% CI −0.95 to 0.72).

Analysis details and source

Adjusted mean change from baseline; negative values mean less pain. SDs of the change were not reported. Analysis included people with at least one follow-up visit, with LOCF.

05
2 months after treatment

Self-assessed heel pain

Participant VAS, pain on first steps in the morning VAS points (cm)

means
GroupnBaselineReported change
Orthospec active shockwaves111—-2.67
Foam-insulated sham54—-1.94

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Difference in adjusted mean change-0.73CI 95% -1.6 to 0.15p = 0.102

Active shockwaves versus sham

Means from analysis of variance adjusted for baseline score and clinical site; last observation carried forward

-1.8Equal results 00.4

At 2 months the difference in self-rated pain was not statistically significant.

Analysis details and source

Adjusted mean change from baseline; negative values mean less pain. SDs of the change were not reported. Analysis included people with at least one follow-up visit, with LOCF.

06
3 months after treatment

Self-assessed heel pain

Participant VAS, pain on first steps in the morning VAS points (cm)

means
GroupnBaselineReported change
Orthospec active shockwaves112—-3.39
Foam-insulated sham56—-1.78

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Difference in adjusted mean change-1.61CI 95% -2.55 to -0.67p <0.001

Active shockwaves versus sham

Means from analysis of variance adjusted for baseline score and clinical site; last observation carried forward

-2.9Equal results 00.3

At 3 months self-rated pain fell 1.61 points more with active treatment.

Analysis details and source

Adjusted mean change from baseline; negative values mean less pain. SDs of the change were not reported. Analysis included people with at least one follow-up visit, with LOCF.

Investigator-rated responders3 reported outcomes
07
1 month after treatment

Investigator-rated responders

Investigator VAS responder people meeting the responder definition

Orthospec active shockwaves22 / 111
Foam-insulated sham9 / 54
OR1.3CI 95% 0.52 to 3.27p = 0.58

Active shockwaves versus sham

Logistic regression including baseline value and clinical site; LOCF

0.4Equal results 14.1

Logarithmic ratio scale.

At 1 month the difference was not statistically significant (OR 1.30, 0.52–3.27).

Analysis details and source

Responder: ≥50% decrease from baseline and a score ≤4 cm. Missing visits were imputed with LOCF; the paper reports these as n/N.

08
2 months after treatment

Investigator-rated responders

Investigator VAS responder people meeting the responder definition

Orthospec active shockwaves38 / 111
Foam-insulated sham9 / 54
OR2.69CI 95% 1.17 to 6.16p = 0.019

Active shockwaves versus sham

Logistic regression including baseline value and clinical site; LOCF

0.8Equal results 17.7

Logarithmic ratio scale.

More responders with active treatment at 2 months.

Analysis details and source

Responder: ≥50% decrease from baseline and a score ≤4 cm. Missing visits were imputed with LOCF; the paper reports these as n/N.

09
3 months after treatment

Investigator-rated responders

Investigator VAS responder people meeting the responder definition

Orthospec active shockwaves48 / 112
Foam-insulated sham11 / 56
OR3.13CI 95% 1.46 to 6.73p = 0.003

Active shockwaves versus sham

Logistic regression including baseline value and clinical site; LOCF

0.8Equal results 18.5

Logarithmic ratio scale.

At 3 months 48 of 112 versus 11 of 56 met the responder definition.

Analysis details and source

Responder: ≥50% decrease from baseline and a score ≤4 cm. Missing visits were imputed with LOCF; the paper reports these as n/N.

Self-rated responders3 reported outcomes
10
1 month after treatment

Self-rated responders

Participant VAS responder people meeting the responder definition

Orthospec active shockwaves39 / 110
Foam-insulated sham17 / 54
OR1.2CI 95% 0.6 to 2.41p = 0.61

Active shockwaves versus sham

Logistic regression including baseline value and clinical site; LOCF

0.5Equal results 12.8

Logarithmic ratio scale.

At 1 month the difference was not statistically significant (OR 1.20, 0.60–2.41).

Analysis details and source

Responder: ≥50% decrease from baseline and a score ≤4 cm. Missing visits were imputed with LOCF; the paper reports these as n/N.

11
2 months after treatment

Self-rated responders

Participant VAS responder people meeting the responder definition

Orthospec active shockwaves48 / 111
Foam-insulated sham17 / 54
OR1.67CI 95% 0.84 to 3.32p = 0.14

Active shockwaves versus sham

Logistic regression including baseline value and clinical site; LOCF

0.7Equal results 13.9

Logarithmic ratio scale.

The 2-month difference was not statistically significant.

Analysis details and source

Responder: ≥50% decrease from baseline and a score ≤4 cm. Missing visits were imputed with LOCF; the paper reports these as n/N.

12
3 months after treatment

Self-rated responders

Participant VAS responder people meeting the responder definition

Orthospec active shockwaves59 / 112
Foam-insulated sham16 / 56
OR2.85CI 95% 1.42 to 5.69p = 0.003

Active shockwaves versus sham

Logistic regression including baseline value and clinical site; LOCF

0.8Equal results 17

Logarithmic ratio scale.

At 3 months 59 of 112 versus 16 of 56 met the responder definition.

Analysis details and source

Responder: ≥50% decrease from baseline and a score ≤4 cm. Missing visits were imputed with LOCF; the paper reports these as n/N.

Activity and function responders3 reported outcomes
13
1 month after treatment

Activity and function responders

Participant diary activity and function people meeting the responder definition

Orthospec active shockwaves60 / 111
Foam-insulated sham31 / 54
OR0.82CI 95% 0.41 to 1.66p = 0.58

Active shockwaves versus sham

Logistic regression including baseline value and clinical site; LOCF

0.3Equal results 12

Logarithmic ratio scale.

At 1 month the difference was not statistically significant (OR 0.82, 0.41–1.66).

Analysis details and source

Responder: improvement of ≥1 point or maintenance of a baseline score of 0 or 1 in the diary activity/function category; LOCF.

14
2 months after treatment

Activity and function responders

Participant diary activity and function people meeting the responder definition

Orthospec active shockwaves64 / 111
Foam-insulated sham27 / 54
OR1.32CI 95% 0.66 to 2.65p = 0.43

Active shockwaves versus sham

Logistic regression including baseline value and clinical site; LOCF

0.6Equal results 13.1

Logarithmic ratio scale.

The 2-month difference was not statistically significant.

Analysis details and source

Responder: improvement of ≥1 point or maintenance of a baseline score of 0 or 1 in the diary activity/function category; LOCF.

15
3 months after treatment

Activity and function responders

Participant diary activity and function people meeting the responder definition

Orthospec active shockwaves72 / 112
Foam-insulated sham32 / 56
OR1.42CI 95% 0.7 to 2.85p = 0.33

Active shockwaves versus sham

Logistic regression including baseline value and clinical site; LOCF

0.6Equal results 13.4

Logarithmic ratio scale.

At 3 months 72 of 112 versus 32 of 56 met the activity and function definition; the difference was not statistically significant.

Analysis details and source

Responder: improvement of ≥1 point or maintenance of a baseline score of 0 or 1 in the diary activity/function category; LOCF.

Decreased analgesic use1 reported outcome
16
3 months after treatment

Decreased analgesic use

Participant diary, change in pain medication since enrolment people reporting decreased use

Orthospec active shockwaves34 / 100
Foam-insulated sham7 / 51
REPORTED COMPARISON TESTp <0.001

Active versus sham across increase, no change and decrease

Cochran–Mantel–Haenszel, stratified by site, scores 1/0/−1

At 3 months 34/100 active versus 7/51 sham reported less analgesic use and 1/100 versus 6/51 reported more. Month 2: decrease 28/95 versus 9/47 (p=.028); month 1: p=.083.

Analysis details and source

Observed diary denominators (100 and 51), not imputed. The test compares all three categories (increase, no change, decrease), not the decrease proportion alone.

Energy level above 4.5 (post hoc)1 reported outcome
19
3 months after treatment

Energy level above 4.5 (post hoc)

qualitative finding

Restricting the active group to people who tolerated level >4.5 (Table 10: 88 versus 52 placebo), investigator pain change was −2.98 versus −1.69 (p=.011) and self-rated −3.95 versus −1.82 (p<.001); activity and function response 67.0% versus 56.1% (p=.16).

Analysis details and source

Post hoc subset chosen by tolerated energy after randomization, so it is not a randomized comparison. The 88 and 52 denominators are not explained, and Figure 5 reports a placebo month-3 change of 1.96, not 1.69.

Sex, age and weight subgroups1 reported outcome
20
3 months after treatment

Sex, age and weight subgroups

qualitative finding

Interaction tests for investigator pain at 3 months were not significant for sex (p=.15), age (p=.89) or weight (p=.35). Differences ranged from −0.21 (161–192 lb) to −1.91 (men; ≥193 lb).

Analysis details and source

Nonsignificant interaction tests in small subgroups do not show that the effect is the same in each subgroup, as the Discussion implies.

How treatment was delivered
Device

Orthospec (Medispec): electrohydraulic spark-gap generator in a water-filled semi-ellipsoid chamber, delivered through a rubber contact membrane to a 35-mm therapy zone. The paper does not call it focused or radial and gives no energy flux density in mJ/mm² for its levels.

Dose and session

One 25-minute session; 3,800 shocks at 150 per minute, delivered continuously from energy level 1, rising every 3 min 35 s to level 7; the unblinded operator lowered the level if not tolerated. Highest level reached among 115: 2–4.5 in 14, 4.6–5.9 in 12, 6–6.9 in 54, ≥7 in 35.

Anaesthesia and targeting

No local or systemic anaesthesia or sedation; ultrasound gel on membrane and heel; no ultrasonic or radiographic targeting.

Sham

Foam-insulated contact membrane to absorb the shockwaves and block most of the energy; same appearance and identical procedure, with the audible sound; ear protection offered. The authors state the sham was not a pure placebo.

Washout and co-interventions

Before treatment: 6 weeks without corticosteroid injection, 48 hours without NSAIDs or analgesics, 2 weeks without physical therapy. People continuing physical therapy or other conservative care were excluded; NSAIDs or analgesics were avoided for 48 hours before each follow-up visit.

Assessments

Blinded investigator assessment: standardized pressure on the heel with the calibrated PressureSpec applicator, pain marked on a 10-point VAS; participants also rated first-steps pain; activity (blocks walked) and analgesic use from diaries. Efficacy visits at 1, 2 and 3 months; safety visits at 6 and 12 months.

HARMS & TOLERABILITY

No serious adverse events. No placebo participant (N=57) had an adverse event. Three of 115 active participants had one event each: two bruising at the treated heel (1.7%), judged device-related, and one local swelling (0.9%), judged unrelated; energy levels 4.5–7. The Results first describe all three events as at least possibly device-related, then classify the swelling as unrelated. The Results call them mild or moderate, the Discussion mild and resolved within days. Safety visits ran to 12 months, but only 78 and 40 people attended then.

LIMITS OF THE ANALYSIS

Funding and role of sponsor: Medispec, the device maker, sponsored this FDA investigational-device phase-3 trial, provided the shockwave and pressure devices, funded the investigation, and a Medispec employee did site management and monitoring. Author conflicts are not otherwise stated.

Primary result is small and borderline (−0.94, 95% CI −1.87 to −0.02); at 1 month the difference was not statistically significant (−0.34, −1.06 to 0.37), and activity/function differences were not statistically significant at any month (3 months OR 1.42, 0.70–2.85). The Summary statement that all heel-pain assessments were significant does not hold for month 1.

Missing data: 172 randomized, 168 analysed with at least one follow-up visit, 152 completed the 12-week efficacy period; LOCF was used. Randomization planned 183 people (122 versus 61) for 80% power; 172 were randomized.

Internal inconsistencies: Results say 89 of 115 tolerated energy level ≥6, the Discussion says the same 89 tolerated ≥4.5; Figure 5 placebo month-3 change 1.96 versus Table 10 −1.69; Table 10 denominators (88, 52) unexplained. Blinding was assessed after the session but the result is not reported.

Author-reported limits: no quality-of-life or foot-specific instrument; efficacy measured only to 3 months; diaries open to bias; the sham may have delivered some energy; bilateral cases excluded, limiting generalizability.

Extractor note: the Orthospec is described as an electrohydraulic semi-ellipsoid reflector device; the paper does not call it radial. Some later reviews (Sun 2017) pool this trial as radial shockwave therapy.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • Funding and role of sponsor: Medispec, the device maker, sponsored this FDA investigational-device phase-3 trial, provided the shockwave and pressure devices, funded the investigation, and a Medispec employee did site management and monitoring. Author conflicts are not otherwise stated.
  • Primary result is small and borderline (−0.94, 95% CI −1.87 to −0.02); at 1 month the difference was not statistically significant (−0.34, −1.06 to 0.37), and activity/function differences were not statistically significant at any month (3 months OR 1.42, 0.70–2.85). The Summary statement that all heel-pain assessments were significant does not hold for month 1.
  • Missing data: 172 randomized, 168 analysed with at least one follow-up visit, 152 completed the 12-week efficacy period; LOCF was used. Randomization planned 183 people (122 versus 61) for 80% power; 172 were randomized.
  • Internal inconsistencies: Results say 89 of 115 tolerated energy level ≥6, the Discussion says the same 89 tolerated ≥4.5; Figure 5 placebo month-3 change 1.96 versus Table 10 −1.69; Table 10 denominators (88, 52) unexplained. Blinding was assessed after the session but the result is not reported.
  • Author-reported limits: no quality-of-life or foot-specific instrument; efficacy measured only to 3 months; diaries open to bias; the sham may have delivered some energy; bilateral cases excluded, limiting generalizability.
  • Extractor note: the Orthospec is described as an electrohydraulic semi-ellipsoid reflector device; the paper does not call it radial. Some later reviews (Sun 2017) pool this trial as radial shockwave therapy.
Research review

Source-linked critical reading

Randomized trial

Reading depthMaterial consulted
Technical source record

Complete local PDF read (all 15 pages): methods, results, all 13 tables and 7 figures, discussion, disclosure, acknowledgments and references. No supplement or protocol document was available.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Study design

Randomized 2:1, double-blind, sham-controlled trial at three US centres (October 2003 to December 2004), run as an FDA investigational-device phase-3 study sponsored by the device maker. 172 randomized (115 active, 57 sham); 168 with at least one follow-up analysed with last observation carried forward.

Participants and setting

172 adults with proximal plantar fasciitis for over 6 months despite at least 4 months of professional care and two drug plus two non-drug treatments; heel pain ≥5 cm on the VAS; one heel per person, bilateral cases excluded. Mean age 51 years, 33% men, 87% white, mean pain duration 30 months; three US centres, 2003–2004.

Treatment

Single 25-minute session: 3,800 shocks at 150 per minute from an electrohydraulic spark-gap device with a 35-mm treatment zone, energy raised from level 1 to 7 as tolerated, no anaesthesia and no imaging guidance. Energy levels are not given in mJ/mm². 89 of 115 reached level 6 or higher.

Comparison

The same procedure with a foam-insulated membrane that absorbed most of the energy and looked identical. Recent steroid injections, NSAIDs and physical therapy were stopped beforehand, and other heel treatments were not continued.

Outcomes and timing

Primary: change in blinded investigator-rated heel pain (standardized pressure, 10-point VAS) from baseline to 3 months. Secondary: self-rated first-steps pain, responder rates (≥50% fall and ≤4 cm), diary activity and function, and analgesic use at 1, 2 and 3 months; adverse events to 12 months.

What the results show

At 3 months investigator-rated pain fell 2.51 versus 1.57 points, difference −0.94 (95% CI −1.87 to −0.02), p=.045; at 1 month −0.34 (−1.06 to 0.37). Self-rated pain at 3 months: −3.39 versus −1.78, difference −1.61 (−2.55 to −0.67); at 1 and 2 months the differences were not significant. Responders at 3 months: 48/112 versus 11/56 by investigator and 59/112 versus 16/56 by self-rating. Activity and function differences were not statistically significant at any month (3 months 72/112 versus 32/56, OR 1.42, 0.70–2.85, p=.33). With a heel spur the pain difference was −0.07 (−1.66 to 1.52).

Harms

No serious adverse events. No placebo participant (N=57) had an adverse event. Three of 115 active participants had one event each: two bruising at the treated heel (1.7%), judged device-related, and one local swelling (0.9%), judged unrelated; energy levels 4.5–7. The Results first describe all three events as at least possibly device-related, then classify the swelling as unrelated. The Results call them mild or moderate, the Discussion mild and resolved within days. Safety visits ran to 12 months, but only 78 and 40 people attended then.

Limits and disclosures

The device maker sponsored and funded the trial, supplied devices and monitored sites. The primary difference was small, its interval nearly reached zero, and LOCF filled missing visits. Energy-level analyses were post hoc and nonrandomized, with unexplained denominators and a Figure 5 versus Table 10 mismatch (1.96 versus −1.69). The Results and Discussion disagree on the energy level the same 89 people tolerated (≥6 versus ≥4.5). Blinding was assessed but not reported, and the authors note the sham may have delivered some energy. No quality-of-life measure; efficacy only to 3 months; bilateral cases excluded.

Application to care

Applies to adults with one painful heel for over 6 months after several conservative treatments, treated with this specific electrohydraulic device without anaesthesia. It suggests a modest pain difference at 3 months; it does not show better walking function, a benefit in people with heel spurs, or what happens after 3 months. Dose findings by energy level are hypothesis-generating.

What remains to be tested

Independent trials with a checked sham, analysis of every randomized participant, function and quality-of-life outcomes, and efficacy follow-up beyond 3 months.

THE ORIGINAL SOURCE

Read the original article.

Extracorporeal shockwave therapy versus placebo for the treatment of chronic proximal plantar fasciitis: results of a randomized, placebo-controlled, double-blinded, multicenter intervention trial.

Malay DS, Pressman MM, Assili A, Kline JT, York S, Buren B, Heyman ER, Borowsky P, LeMay C. · J Foot Ankle Surg · 2006

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →